Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain

Neurology

Volumn 62, Issue 6, 2004, Pages 925-931

  Ingelsson, M ^a   Fukumoto, H ^a   Newell, K L ^a   Growdon, J H ^a   Hedley Whyte, E T ^a   Frosch, M P ^a   Albert, M S ^a   Hyman, B T ^a   Irizarry, M C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; FORMIC ACID; GLIAL FIBRILLARY ACIDIC PROTEIN; SYNAPTOPHYSIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; ASSOCIATION CORTEX; BRAIN; CONTROLLED STUDY; DENSITY; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOSIS; HUMAN; HUMAN TISSUE; NEUROANATOMY; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; STEREOMETRY; SYNAPSE; TEMPORAL CORTEX; TIME; UNITED STATES; GENETICS; METABOLISM; PATHOLOGY; PREDICTION AND FORECASTING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; BRAIN; DISEASE PROGRESSION; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOSIS; HUMANS; NEUROFIBRILLARY TANGLES; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; SYNAPSES; SYNAPTOPHYSIN;

EID: 1842510004     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000115115.98960.37     Document Type: Article

References (42)

1. Hirano A, Zimmerman H. Alzheimer's neurofibrillary changes-a topographical study. Arch Neurol 1962;7:227-242.
2. Hyman B, Van Horsen G, Damasio A, Barnes C. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984;225:1168-1170.
3. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
4. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-639.
5. Gomez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997;41:17-24.
6. Riley K, Snowdon D, Markesbery WR. Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann Neurol 2002;51:567-577.
7. Giannakopoulos P, Herrmann F, Bussière T, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003;60:1495-1500.
8. Guillozet A, Weintraub S, Mash D, Mesulam M. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 2003;60:729-736.
9. West M. Regionally specific loss of neurons in the aging human hippocampus. Neurobiol Aging 1993;14:287-293.
10. Kril J, Patel S, Harding A, Halliday G. Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathol 2002;103:370-376.
11. Davies C, Mann D, Sumpter P, Yates P. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci 1987;78:151-164.
12. Masliah E, Terry R, Alford M, DeTeresa R, Hansen L. Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease. Am J Pathol 1991;138:235-246.
13. Heinonen O, Soininen H, Sorvari H, et al. Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in Alzheimer's disease. Neuroscience 1995;64:375-384.
14. Hansen L, Daniel S, Wilcock G, Love S. Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer's disease and dementia. J Neurol Neurosurg Psychiatry 1998;64:653-656.
15. Arnold S, Hyman BT, Flory J, Damasio A, van Hoesen G. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex 1991;1:103-116.
16. Roher A, Lowenson J, Clarke S, et al. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 1993;268:3072-3083.
17. Roher A, Lowenson J, Clarke S, et al. Beta-amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci USA 1993;90:10836-10840.
18. Mann D, Iwatsubo T, Ihara Y, et al. Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene. Am J Pathol 1996;148:1257-1266.
19. Bitan G, Kirkitadze M, Lomakin A, Vollers S, Benedek G, Teplow D. Amyloid β-protein (Aβ) assembly. Aβ40 and Aβ42 oligomerize through distinct pathways. Proc Natl Acad Sci USA 2003;100:330-335.
20. Jarrett J, Berger E, Lansbury PJ. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993;11:4693-4697.
21. Funato H, Yoshimura M, Kusui K, et al. Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease. Am J Pathol 1998;152:1633-1640.
22. Näslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 2000;283:1571-1577.
23. McGeer P, McGeer E, Yasojima K. Alzheimer disease and neuroinflammation. J Neural Transm 2000;59:53-57.
24. McKhann G, Drachman D, Folstein M. Clinical diagnosis of Alzheimer's disease: report of NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Forces on Alzheimer's Disease. Neurology 1984;34:939-944.
25. Mirra SS, Heyman A, McKeel D. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
26. Hyman B, Trojanowski J. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease. J Neuropathol Exp Neurol 1997;56:1095-1097.
27. Vonsattel J, Aizawa H, Ge P, et al. An improved approach to prepare human brains for research. J Neuropathol Exp Neurol 1995;54:42-56.
28. Honer W, Hu L, Davies P. Human synaptic proteins with a heterogeneous distribution in cerebellum and visual cortex. Brain Res 1993;609:9-20.
29. Fukumoto H, Cheung B, Hyman B, Irizarry M. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 2002;59:1381-1389.
30. Brown D, Risser R, Bigio E, et al. Neocortical synapse density and Braak stage in the Lewy body variant of Alzheimer disease: a comparison with classic Alzheimer disease and normal aging. J Neuropathol Exp Neurol 1998;57:955-960.
31. Fukumoto H, Tomita T, Matsunaga H, Ishibashi Y, Saido T, Iwatsubo T. Primary cultures of neuronal and non-neuronal rat brain cells secrete similar proportions of amyloid beta peptides ending at A beta40 and A beta42. Neuroreport 1999;10:2965-2969.
32. Hyman B, Marzloff K, Arriagada P, Iannicola C. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol 1993;52:594-600.
33. Gomez-Isla T, West H, Rebeck G, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 1996;39:62-70.
34. Dickson D, Crystal H, Bevona C, Honer W, Vincent I, Davies P. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 1995;16:285-298.
35. Gomez-Isla T, Price J, McKeel DJ, Morris J, Growdon J, Hyman B. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996;16:4491-4500.
36. Price J, Ko AI, Wade M, Tsou S, McKeel D, Morris J. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 2001;58:1395-1402.
37. Griffin W, Sheng J, Roberts G, Mrak R. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol 1995;54:276-281.
38. Fukumoto H, Asami-Odaka A, Suzuki N, Iwatsubo T. Association of Aβ40-positive senile plaques with microglial cells in the brains of patients with Alzheimer's disease and in non-demented aged individuals. Neurodegeneration 1996;5:13-17.
39. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2:864-870.
40. Rebeck G, Reiter J, Strickland D, Hyman B. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993;11:575-580.
41. Schmechel DE. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:9649-9653.
42. Locascio J, Growdon J, Corkin S. Cognitive test performance in detecting, staging and tracking Alzheimer's disease. Arch Neurol 1995;52:1087-1099.